Drug intelligence / Profile preview

Jia Wei Niu Bang Zi granule + methotrexate

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Jia Wei Niu Bang Zi granule (NBZG) is a traditional Chinese medicine formulation combined with methotrexate, a conventional disease-modifying antirheumatic drug (DMARD), for the treatment of active rheumatoid arthritis (RA). NBZG has been used for decades at Longhua Hospital to treat RA. Its key component, Niu Bang Zi (Arctium lappa or Burdock Seed), is traditionally used for clearing heat and toxins, detoxification, and has potential antioxidant and antimicrobial properties. The combination aims to potentially enhance efficacy in managing active RA.

Other names: NBZG + methotrexate

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Jia Wei Niu Bang Zi granule + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jia Wei Niu Bang Zi granule + methotrexate.

Explore the full profile